{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:38:09Z","timestamp":1793151489510,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Juvenile Idiopathic Arthritis is one of the most prevalent chronic diseases in children, with an annual incidence of 2\u201320 cases per 100,000 and a prevalence of 16\u2013150 per 100,000. It is associated with several complications that can cause short-term or long-term disability and reduce the quality of life. Among these, growth and pubertal disorders play an important role. Chronic inflammatory conditions are often associated with growth failure ranging from slight decrease in height velocity to severe forms of short stature. The prevalence of short stature in JIA varies from 10.4% in children with polyarticular disease to 41% of patients with the systemic form, while oligoarthritis is mostly associated with localized excessive bone growth of the affected limb, leading to limb dissymmetry. The pathogenesis of growth disorders is multifactorial and includes the role of chronic inflammation, long-term use of corticosteroids, undernutrition, altered body composition, delay of pubertal onset or slow pubertal progression. These factors can exert a systemic effect on the GH\/IGF-1 axis and on the GnRH-gonadotropin-gonadic axis, or a local influence on the growth plate homeostasis and function<jats:bold>.<\/jats:bold> Although new therapeutic options are available to control inflammation, there are still 10\u201320% of patients with severe forms of the disease who show continuous growth impairment, ending in a short final stature. Moreover, delayed puberty is associated with a reduction in the peak bone mass with the possibility of concomitant or future bone fragility. Monitoring of puberty and bone health is essential for a complete health assessment of adolescents with JIA. In these patients, an assessment of the pubertal stage every 6\u2009months from the age of 9\u2009years is recommended. Also, linear growth should be always evaluated considering the patient\u2019s bone age. The impact of rhGH therapy in children with JIA is still unclear, but it has been shown that if rhGH is added at high dose in a low-inflammatory condition, post steroids and on biologic therapy, it is able to favor a prepubertal growth acceleration, comparable with the catch-up growth response in GH-deficient patients<jats:bold>.<\/jats:bold> Here we provide a comprehensive review of the pathogenesis of puberty and growth disorders in children with JIA, which can help the pediatrician to properly and timely assess the presence of growth and pubertal disorders in JIA patients.<\/jats:p>","DOI":"10.1186\/s12969-021-00521-5","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T12:06:50Z","timestamp":1615550810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Growth and puberty in children with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"19","author":[{"given":"Debora Mariarita","family":"d\u2019Angelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-1495","authenticated-orcid":false,"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"9563","key":"521_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile Idiopathic Arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet."},{"issue":"9783","key":"521_CR2","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, et al. Juvenile Idiopathic Arthritis. Lancet. 2011;377(9783):2138\u201349.","journal-title":"Lancet."},{"issue":"2","key":"521_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390\u20132.","journal-title":"J Rheumatol."},{"issue":"6","key":"521_CR4","first-page":"1296","volume":"29","author":"D Simon","year":"2002","unstructured":"Simon D, Fernando C, et al. Linear Growth and Final Height in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Longterm Glucocorticoids. J Rheumatol. 2002 Jun;29(6):1296\u2013300.","journal-title":"J Rheumatol."},{"issue":"6","key":"521_CR5","first-page":"1011","volume":"18","author":"VE MacRae","year":"2006","unstructured":"MacRae VE, Wong SC, et al. Cytokine Actions in Growth Disorders Associated With Pediatric Chronic Inflammatory Diseases (Review). Int J Mol Med. 2006;18(6):1011\u20138.","journal-title":"Int J Mol Med."},{"issue":"1","key":"521_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.11.002","volume":"48","author":"F McErlane","year":"2018","unstructured":"McErlane F, Carrasco R, et al. Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum. 2018;48(1):53\u201360.","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"521_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-017-0196-7","volume":"15","author":"J Guzman","year":"2017","unstructured":"Guzman J, Kerr T, et al. Growth and Weight Gain in Children With Juvenile Idiopathic Arthritis: Results From the ReACCh-Out Cohort. Pediatr Rheumatol Online J. 2017;15(1):68.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"4","key":"521_CR8","first-page":"157","volume":"64","author":"O Nilsson","year":"2005","unstructured":"Nilsson O, Marino R, et al. Endocine regulation of the growth plate. Horm Res. 2005;64(4):157\u201365.","journal-title":"Horm Res."},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1242\/dmm.006775","volume":"4","author":"S Elis","year":"2011","unstructured":"Elis S, Wu Y, et al. Unbound (biovailable) IGF1 enhances somatic growth. Dis Model Mech. 2011;4:649\u201358.","journal-title":"Dis Model Mech."},{"issue":"1","key":"521_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1210\/er.2015-1026","volume":"37","author":"SC Wong","year":"2016","unstructured":"Wong SC, Dobie R, et al. Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions. Endocr Rev. 2016 Feb;37(1):62\u2013110.","journal-title":"Endocr Rev."},{"key":"521_CR11","first-page":"104","volume":"29","author":"S Gaspari","year":"2011","unstructured":"Gaspari S, Marcovecchio ML, et al. Growth in juvenile idiopathic arthritis: the role of inflammation. Clin Exp Rheumatol. 2011;29:104\u201310.","journal-title":"Clin Exp Rheumatol."},{"issue":"9","key":"521_CR12","first-page":"31","volume":"18","author":"F Cirillo","year":"1878","unstructured":"Cirillo F, Lazzeroni P, et al. Inflammatory diseases and growth: effects on the GH-IGF axis and on growth plate. Int J Mol Sci. 2017 Aug. 1878;18(9):31.","journal-title":"Int J Mol Sci. 2017 Aug"},{"issue":"3","key":"521_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2265.2007.02908.x","volume":"67","author":"VE MacRae","year":"2007","unstructured":"MacRae VE, Wong SC, et al. Cytokine profiling and in vitro studies of murine bone growth using biological fluids from children with juvenile idiopathic arthritis. Clin Endocrinol (Oxf). 2007 Sep;67(3):442\u20138.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1210\/endo.142.11.8511","volume":"142","author":"F De Benedetti","year":"2001","unstructured":"De Benedetti F, Meazza C, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818\u201326.","journal-title":"Endocrinology."},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00467-012-2271-0","volume":"28","author":"C Farquharson","year":"2013","unstructured":"Farquharson C, Ahmed SF. Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH\/IGF1 signaling. Pediatr Nephrol. 2013;28:547\u201356.","journal-title":"Pediatr Nephrol."},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/pr.2014.84","volume":"76","author":"D Choukair","year":"2014","unstructured":"Choukair D, Hugel U, et al. Inhibition of IGF1-related intracellular signaling pathways by proinflammatory cytokines in growth plate chondrocytes. Pediatr Res. 2014;76:245\u201351.","journal-title":"Pediatr Res."},{"key":"521_CR17","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.4049\/jimmunol.172.12.7713","volume":"172","author":"SR Broussard","year":"2004","unstructured":"Broussard SR, McCusker RH, et al. IL-1\u03b2 impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptors in myoblasts. J Immunol. 2004;172:7713\u201320.","journal-title":"J Immunol."},{"key":"521_CR18","first-page":"E430","volume":"M270","author":"CH Lang","year":"1996","unstructured":"Lang CH, Fan J, et al. IL-1 receptor antagonist attenuates sepsis-indiced alterations in the IGF system and protein synthesis. Am J Physiol Endoc. 1996;M270:E430\u20137.","journal-title":"Am J Physiol Endoc."},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1677\/joe.1.06609","volume":"189","author":"VE MacRae","year":"2006","unstructured":"MacRae VE, Farquharson C, et al. The restricted potential of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol. 2006;189:319\u201328.","journal-title":"J Endocrinol."},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1074\/jbc.M110773200","volume":"278","author":"F Legendre","year":"2003","unstructured":"Legendre F, Dudhia J, et al. JAK\/STAT but not ERK1\/ERK2 pathway mediates interleukin (IL)-6\/soluble IL-6R down regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of Sox-9 expression. J Biol Chem. 2003;278:2903\u201312.","journal-title":"J Biol Chem."},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1002\/art.22175","volume":"54","author":"F De Benedetti","year":"2006","unstructured":"De Benedetti F, Rucci N, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551\u201363.","journal-title":"Arthritis Rheum."},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12979","volume":"189","author":"C Wehmeyer","year":"2017","unstructured":"Wehmeyer C, Pap T, et al. The role of stromal cells in inflammatory bone loss. Clin Exp Immunol. 2017;189:1\u201311.","journal-title":"Clin Exp Immunol."},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/s10165-008-0115-3","volume":"19","author":"S Nakajima","year":"2009","unstructured":"Nakajima S, Naruto T, et al. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2009;19:42\u20136.","journal-title":"Mod Rheumatol."},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1074\/jbc.275.5.3687","volume":"275","author":"S Murakami","year":"2000","unstructured":"Murakami S, Lefebvre V, et al. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necroisis factor-alpha. J Biol Chem. 2000;275:3687\u201392.","journal-title":"J Biol Chem."},{"key":"521_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/jcb.20192","volume":"93","author":"T Fujita","year":"2004","unstructured":"Fujita T, Fukayama R, et al. Dexamethasone inhibits insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt signaling and DNA binding of Runx2. J Cell Biochem. 2004;93:374\u201383.","journal-title":"J Cell Biochem"},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1677\/joe.0.1750705","volume":"175","author":"T Mushtaq","year":"2002","unstructured":"Mushtaq T, Farquharson C, et al. Glucocorticoid effects on chondrogenesis, differentiation and apoptosis in the murine ATDC5 chondrocyte cell line. J Endocrinol. 2002;175:705\u201313.","journal-title":"J Endocrinol."},{"key":"521_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.toxlet.2013.10.020","volume":"224","author":"F Zaman","year":"2014","unstructured":"Zaman F, Chrysis D, et al. Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic Bid. Toxicol Lett. 2014;224:196\u2013200.","journal-title":"Toxicol Lett."},{"key":"521_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s100670200098","volume":"21","author":"SJ Wang","year":"2002","unstructured":"Wang SJ, Yang YH, et al. Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol. 2002;21:363\u20138.","journal-title":"Clin Rheumatol."},{"key":"521_CR29","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3899\/jrheum.080199","volume":"35","author":"LS Souza","year":"2008","unstructured":"Souza LS, Machado SH, et al. Growth velocity and interleukin 6 concentrations in juvenile idiopathis arthritis. J Rheumatol. 2008;35:2265\u201371.","journal-title":"J Rheumatol."},{"key":"521_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/rheumatology\/keh321","volume":"43","author":"LC Rall","year":"2004","unstructured":"Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxf). 2004;43:1219\u201323.","journal-title":"Rheumatology (Oxf)."},{"issue":"38","key":"521_CR31","doi-asserted-by":"publisher","first-page":"27375","DOI":"10.1074\/jbc.M113.462218","volume":"288","author":"S Wu","year":"2013","unstructured":"Wu S, Grunwald T, et al. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J Biol Chem. 2013;288(38):27375\u201383.","journal-title":"J Biol Chem."},{"issue":"1","key":"521_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3899\/jrheum.130311","volume":"41","author":"F Uettwiller","year":"2014","unstructured":"Uettwiller F, Perlbarg J, et al. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis. J Rheumatol. 2014;41(1):128\u201335.","journal-title":"J Rheumatol."},{"key":"521_CR33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/rheumatology\/keq123","volume":"49","author":"AD Billiau","year":"2010","unstructured":"Billiau AD, Loop L, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2010;49:1550\u20138.","journal-title":"Rheumatology."},{"issue":"7","key":"521_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/keu489","volume":"54","author":"L Kearsley-Fleet","year":"2015","unstructured":"Kearsley-Fleet L, Hyrich KL, et al. Growth in Children and Adolescents With Juvenile Idiopathic Arthritis Over 2\u2009Years of Treatment With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxf). 2015 Jul;54(7):1279\u201385.","journal-title":"Rheumatology (Oxf)."},{"key":"521_CR35","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1136\/ard.2005.047225","volume":"65","author":"P Tynjala","year":"2006","unstructured":"Tynjala P, Lahdenne P, et al. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis. 2006;65:2265\u201371.","journal-title":"Ann Rheum Dis."},{"key":"521_CR36","first-page":"2481","volume":"34","author":"PF Vojvodich","year":"2007","unstructured":"Vojvodich PF, Hansen JB, et al. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol. 2007;34:2481\u20135.","journal-title":"J Rheumatol."},{"issue":"Suppl 1","key":"521_CR37","first-page":"20","volume":"72","author":"K Minden","year":"2009","unstructured":"Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(Suppl 1):20\u20135.","journal-title":"Horm Res."},{"key":"521_CR38","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1210\/jc.2007-0544","volume":"92","author":"S Bechtold","year":"2007","unstructured":"Bechtold S, Ripperger P, et al. Growth hormone increases final height in patients with Juvenile Idiopathic Arthritis: data from a randomized controlled study. J Clin Endocrinol Metab. 2007;92:3013\u20138.","journal-title":"J Clin Endocrinol Metab."},{"issue":"suppl 6","key":"521_CR39","first-page":"47","volume":"9","author":"H Svantesson","year":"1991","unstructured":"Svantesson H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis. A pilot study. Clin Exp Rheumatol. 1991;9(suppl 6):47\u201350.","journal-title":"Clin Exp Rheumatol."},{"key":"521_CR40","first-page":"153","volume":"21","author":"UM Davies","year":"1994","unstructured":"Davies UM, Rooney M, et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol. 1994;21:153\u20138.","journal-title":"J Rheumatol."},{"key":"521_CR41","first-page":"1407","volume":"31","author":"S Bechtold","year":"2004","unstructured":"Bechtold S, Ripperger P, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4\u2009years. J Rheumatol. 2004;31:1407\u201312.","journal-title":"J Rheumatol."},{"issue":"11","key":"521_CR42","first-page":"2492","volume":"30","author":"D Simon","year":"2003","unstructured":"Simon D, Lucidarme N, et al. Effects on Growth and Body Composition of Growth Hormone Treatment in Children With Juvenile Idiopathic Arthritis Requiring Steroid Therapy. J Rheumatol. 2003 Nov;30(11):2492\u20139.","journal-title":"J Rheumatol."},{"issue":"6","key":"521_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000313589","volume":"73","author":"E Bismuth","year":"2010","unstructured":"Bismuth E, Chevenne D, et al. Moderate Deterioration in Glucose Tolerance During High-Dose Growth Hormone Therapy in Glucocorticoid-Treated Patients With Juvenile Idiopathic Arthritis. Horm Res Paediatr. 2010;73(6):465\u201372.","journal-title":"Horm Res Paediatr."},{"key":"521_CR44","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1210\/jcem.86.12.8083","volume":"86","author":"S Bechtold","year":"2001","unstructured":"Bechtold S, Ripperger P, et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab. 2001;86:5737\u201344.","journal-title":"J Clin Endocrinol Metab."},{"key":"521_CR45","first-page":"1413","volume":"31","author":"MT Saha","year":"2004","unstructured":"Saha MT, Haapasaari J, et al. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol. 2004;31:1413\u20137.","journal-title":"J Rheumatol."},{"key":"521_CR46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1067\/S0022-3476(03)00390-1","volume":"143","author":"S Bechtold","year":"2003","unstructured":"Bechtold S, Ripperger P, et al. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr. 2003;143:512\u20139.","journal-title":"J Pediatr."},{"key":"521_CR47","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1210\/jc.2006-2877","volume":"92","author":"D Simon","year":"2007","unstructured":"Simon D, Prieur AM, et al. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab. 2007;92:2567\u201373.","journal-title":"J Clin Endocrinol Metab."},{"key":"521_CR48","first-page":"38","volume":"58","author":"MD Perez","year":"2000","unstructured":"Perez MD, Abrams SA, et al. Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x-ray absorptiometry. J Rheumatol Suppl. 2000;58:38\u201343.","journal-title":"J Rheumatol Suppl."},{"issue":"3","key":"521_CR49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/art.20963","volume":"52","author":"G Lien","year":"2005","unstructured":"Lien G, Selvaag AM, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):833\u201340.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"521_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1210\/jc.2009-0979","volume":"95","author":"S Bechtold","year":"2010","unstructured":"Bechtold S, Ripperger P, et al. Dynamics of Body Composition and Bone in Patients With Juvenile Idiopathic Arthritis Treated With Growth Hormone. J Clin Endocrinol Metab. 2010;95(1):178\u201385.","journal-title":"J Clin Endocrinol Metab."},{"key":"521_CR51","first-page":"403","volume":"83","author":"G Touati","year":"1998","unstructured":"Touati G, Prieur AM, et al. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab. 1998;83:403\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"521_CR52","first-page":"38","volume":"68","author":"D Simon","year":"2007","unstructured":"Simon D. rhGH treatment in corticosteroid-treated patients. Horm Res. 2007;68:38\u201345.","journal-title":"Horm Res."},{"issue":"Suppl 1","key":"521_CR53","first-page":"55","volume":"72","author":"D Simon","year":"2009","unstructured":"Simon D, Bechtold S. Effects of Growth Hormone Treatment on Growth in Children With Juvenile Idiopathic Arthritis. Horm Res. 2009;72(Suppl 1):55\u20139.","journal-title":"Horm Res."},{"issue":"3","key":"521_CR54","doi-asserted-by":"publisher","first-page":"101316","DOI":"10.1016\/j.beem.2019.101316","volume":"33","author":"T Raivio","year":"2019","unstructured":"Raivio T, Miettinen PJ. Constitutional delay of puberty versus congenital hypogonadotropic hypogonadism: Genetics, management and updates. Best Pract Res Clin Endocrinol Metab. 2019;33(3):101316.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"3","key":"521_CR55","doi-asserted-by":"publisher","first-page":"101265","DOI":"10.1016\/j.beem.2019.03.001","volume":"33","author":"CL Wood","year":"2019","unstructured":"Wood CL, Lane LC, et al. Puberty: Normal physiology (brief overview). Best Pract Res Clin Endocrinol Metab. 2019;33(3):101265.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"3","key":"521_CR56","doi-asserted-by":"publisher","first-page":"101275","DOI":"10.1016\/j.beem.2019.04.009","volume":"33","author":"KT Kao","year":"2019","unstructured":"Kao KT, Denker M, et al. Pubertal abnormalities in adolescents with chronic disease. Best Pract Res Clin Endocrinol Metab. 2019;33(3):101275.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"2","key":"521_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pop.2020.02.001","volume":"47","author":"SV Elchuri","year":"2020","unstructured":"Elchuri SV, Momen JJ. Disorders of Pubertal Onset. Prim Care. 2020;47(2):189\u2013216.","journal-title":"Prim Care."},{"issue":"Suppl 2","key":"521_CR58","first-page":"285","volume":"16","author":"R Rusconi","year":"2003","unstructured":"Rusconi R, Corona F, et al. Age at menarche in juvenile rheumatoid arthritis. J Pediatr Endocrinol Metab. 2003;16(Suppl 2):285\u20138.","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"8","key":"521_CR59","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00296-013-2683-6","volume":"33","author":"SE Maher","year":"2013","unstructured":"Maher SE, Ali FI. Sexual maturation in Egyptian boys and girls with juvenile rheumatoid arthritis. Rheumatol Int. 2013;33(8):2123\u20136.","journal-title":"Rheumatol Int."},{"issue":"5","key":"521_CR60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00296-013-2737-9","volume":"34","author":"D El Badri","year":"2014","unstructured":"El Badri D, Rostom S, et al. Sexual maturation in Moroccan patients with juvenile idiopathic arthritis. Rheumatol Int. 2014;34(5):665\u20138.","journal-title":"Rheumatol Int."},{"key":"521_CR61","doi-asserted-by":"publisher","first-page":"443e53","DOI":"10.1056\/NEJMcp1109290","volume":"366","author":"MR Palmert","year":"2012","unstructured":"Palmert MR, Dunkel L. Clinical practice, Delayed puberty. N Engl J Med. 2012;366:443e53.","journal-title":"N Engl J Med."},{"issue":"7","key":"521_CR62","first-page":"1783","volume":"27","author":"M Ostensen","year":"2000","unstructured":"Ostensen M, Almberg K, et al. Sex, reproduction, and gynecological disease in young adults with a history of juvenile chronic arthritis. J Rheumatol. 2000;27(7):1783\u20137.","journal-title":"J Rheumatol."},{"issue":"1","key":"521_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jped.2018.07.015","volume":"96","author":"SH Machado","year":"2020","unstructured":"Machado SH, Xavier RM, et al. Height and sexual maturation in girls with juvenile idiopathic arthritis. J Pediatr (Rio J). 2020;96(1):100\u20137.","journal-title":"J Pediatr (Rio J)."},{"issue":"Suppl 2","key":"521_CR64","first-page":"53","volume":"57","author":"D Simon","year":"2002","unstructured":"Simon D. Puberty in chronically diseased patients. Horm Res. 2002;57(Suppl 2):53\u20136.","journal-title":"Horm Res."},{"issue":"2","key":"521_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/10253890.2016.1149695","volume":"19","author":"MS Izvolskaia","year":"2016","unstructured":"Izvolskaia MS, Tillet Y, et al. Disruptions in the hypothalamic-pituitary-gonadal axis in rat offspring following prenatal maternal exposure to lipopolysaccharide. Stress. 2016;19(2):198\u2013205.","journal-title":"Stress."},{"issue":"4","key":"521_CR66","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1210\/endo-126-4-2145","volume":"126","author":"PS Kalra","year":"1990","unstructured":"Kalra PS, Sahu A, et al. Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats. Endocrinology. 1990;126(4):2145\u201352.","journal-title":"Endocrinology."},{"issue":"5","key":"521_CR67","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1210\/endo-127-5-2381","volume":"127","author":"PS Kalra","year":"1990","unstructured":"Kalra PS, Fuentes M, et al. Endogenous opioid peptides mediate the interleukin-1-induced inhibition of the release of luteinizing hormone (LH)-releasing hormone and LH. Endocrinology. 1990;127(5):2381\u20136.","journal-title":"Endocrinology."},{"issue":"2","key":"521_CR68","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1210\/endo-127-2-849","volume":"127","author":"C Rivier","year":"1990","unstructured":"Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology. 1990;127(2):849\u201356.","journal-title":"Endocrinology."},{"key":"521_CR69","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1210\/en.2003-0644","volume":"144","author":"H Watanobe","year":"2003","unstructured":"Watanobe H, Hayakawa Y. Hypothalamic Interleukin-1\u03b2 and Tumor Necrosis Factor-\u03b1, but Not Interleukin-6, Mediate the Endotoxin-Induced Suppression of the Reproductive Axis in Rats. Endocrinology. 2003;144:4868\u201375.","journal-title":"Endocrinology."},{"key":"521_CR70","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1071\/RD18277","volume":"31","author":"CY Lee","year":"2019","unstructured":"Lee CY, Li SY, et al. Lipopolysaccharide reduces gonadotrophin-releasing hormone (GnRH) gene expression: Role of RFamide-related peptide-3 and kisspeptin. Reprod Fertil Dev. 2019;31:1134\u201343.","journal-title":"Reprod Fertil Dev."},{"issue":"1","key":"521_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2826.2011.02162.x","volume":"24","author":"AR Khan","year":"2012","unstructured":"Khan AR, Kauffman AS. The role of kisspeptin and RFamide-related peptide-3 neurones in the circadian-timed preovulatory luteinising hormone surge. J Neuroendocrinol. 2012;24(1):131\u201343.","journal-title":"J Neuroendocrinol."},{"key":"521_CR72","first-page":"46","volume":"102","author":"E Sarchielli","year":"2017","unstructured":"Sarchielli E, Comeglio P, et al. Tumor necrosis factor-\u03b1 impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab. 2017;102:46\u201356.","journal-title":"J Clin Endocrinol Metab."},{"key":"521_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.yhbeh.2014.06.007","volume":"66","author":"T Iwasa","year":"2014","unstructured":"Iwasa T, Matsuzaki T, et al. Hypothalamic Kiss1 and RFRP gene expressions are changed by a high dose of lipopolysaccharide in female rats. Horm Behav. 2014;66:309\u201316.","journal-title":"Horm Behav."},{"issue":"1\u20132","key":"521_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mce.2006.06.002","volume":"256","author":"AC Gore","year":"2006","unstructured":"Gore AC, Attardi B, et al. Glucocorticoid repression of the reproductive axis: effects on GnRH and gonadotropin subunit mRNA levels. Mol Cell Endocrinol. 2006;256(1\u20132):40\u20138.","journal-title":"Mol Cell Endocrinol."},{"issue":"2","key":"521_CR75","doi-asserted-by":"publisher","first-page":"330e5","DOI":"10.1095\/biolreprod60.2.330","volume":"60","author":"M Tetsuka","year":"1999","unstructured":"Tetsuka M, Milne M, et al. Expression of 11-beta-hydroxysteroid dehydrogenase, glucocorticoid receptor, and mineralocorticoid receptor genes in rat ovary. Biol Reprod. 1999;60(2):330e5.","journal-title":"Biol Reprod"},{"issue":"5","key":"521_CR76","doi-asserted-by":"publisher","first-page":"774e9","DOI":"10.1210\/jcem-40-5-774","volume":"40","author":"M Sakakura","year":"1975","unstructured":"Sakakura M, Takebe K, et al. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40(5):774e9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"521_CR77","first-page":"571e5","volume":"28","author":"NE Aikawa","year":"2010","unstructured":"Aikawa NE, Sallum AM, et al. Menstrual and hormonal alterations in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(4):571e5.","journal-title":"Clin Exp Rheumatol"},{"key":"521_CR78","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1677\/JOE-08-0568","volume":"2013","author":"R Hardy","year":"2009","unstructured":"Hardy R, Cooper M. Bone loss in inflammatory disorders. J Endocrinol. 2009;2013:309\u201320.","journal-title":"J Endocrinol."},{"issue":"1","key":"521_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5114\/aoms.2010.13501","volume":"6","author":"W Um\u0142awska","year":"2010","unstructured":"Um\u0142awska W, Prusek-Dudkiewicz A. Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis. Arch Med Sci. 2010;6(1):19\u201323.","journal-title":"Arch Med Sci."},{"key":"521_CR80","first-page":"1097","volume":"10","author":"RJ Gordon","year":"2020","unstructured":"Gordon RJ, Gordon CM. Adolescents and Bone Health. Clin Obstet Gynecol. 2020;10:1097.","journal-title":"Clin Obstet Gynecol."},{"issue":"3","key":"521_CR81","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0897190012442066","volume":"25","author":"S Ziglar","year":"2012","unstructured":"Ziglar S, Hunter TS. The effect of hormonal oral contraception on acquisition of peak bone mineral density of adolescents and young women. J Pharm Pract. 2012;25(3):331\u201340.","journal-title":"J Pharm Pract."},{"issue":"1","key":"521_CR82","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpeds.2010.06.054","volume":"158","author":"V Gilsanz","year":"2011","unstructured":"Gilsanz V, Chalfant J, et al. Age at onset of puberty predicts bone mass in young adulthood. J Pediatr. 2011;158(1):100\u2013105.e1052.","journal-title":"J Pediatr"},{"key":"521_CR83","first-page":"341","volume":"9","author":"M Alfredo","year":"2006","unstructured":"Alfredo M. Relationship between delayed menarche and bone mineralization in patients affected by juvenile idiopathic arthritis (JIA). J Clin. Dens. 2006;9:341.","journal-title":"Dens."},{"key":"521_CR84","first-page":"309","volume":"2009","author":"RG Hardy","year":"2013","unstructured":"Hardy RG, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 2013;2009:309\u201320.","journal-title":"J Endocrinol."},{"issue":"3","key":"521_CR85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40272-017-0219-3","volume":"19","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Milojevic D. Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. Paediatr Drugs. 2017;19(3):193\u2013211.","journal-title":"Paediatr Drugs."},{"issue":"3","key":"521_CR86","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/1756-185X.12560","volume":"18","author":"A Jayasena","year":"2015","unstructured":"Jayasena A, Atapattu N, et al. Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review. Int J Rheum Dis. 2015;18(3):287\u201393.","journal-title":"Int J Rheum Dis."},{"issue":"2","key":"521_CR87","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jocd.2014.01.007","volume":"17","author":"CM Gordon","year":"2014","unstructured":"Gordon CM, Leonard MB, et al. 2013 pediatric position development conference: executive summary and reflections. J Clin Densitom. 2014;17(2):219\u201324.","journal-title":"J Clin Densitom"},{"issue":"9","key":"521_CR88","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/jbmr.2511","volume":"30","author":"CM LeBlanc","year":"2015","unstructured":"LeBlanc CM, Ma J, et al. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders. J Bone Miner Res. 2015;30(9):1667\u201375.","journal-title":"J Bone Miner Res."},{"key":"521_CR89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12969-020-0411-9","volume":"18","author":"R Galindo-Zavala","year":"2020","unstructured":"Galindo-Zavala R, Bou-Torrent R, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol. 2020;18:20.","journal-title":"Pediatr Rheumatol."},{"issue":"9","key":"521_CR90","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/adc.2006.093997","volume":"91","author":"J Thornton","year":"2006","unstructured":"Thornton J, Ashcroft DM, et al. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child. 2006;91(9):753\u201361.","journal-title":"Arch Dis Child."},{"issue":"5","key":"521_CR91","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ghir.2012.07.002","volume":"22","author":"S Bechtold","year":"2012","unstructured":"Bechtold S, Beyerlein A, et al. Total Pubertal Growth in Patients With Juvenile Idiopathic Arthritis Treated With Growth Hormone: Analysis of a Single Center. Growth Horm IGF Res. 2012 Oct;22(5):180\u20135.","journal-title":"Growth Horm IGF Res."},{"issue":"5","key":"521_CR92","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000489778","volume":"90","author":"F de Zegher","year":"2018","unstructured":"de Zegher F, Reynaert N, et al. Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies. Horm Res Paediatr. 2018;90(5):337\u201343.","journal-title":"Horm Res Paediatr."},{"issue":"4","key":"521_CR93","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S, Imagawa T, et al. Long term safety and effectiveness of the anti-interleukin-6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014 Apr;41(4):759\u201367.","journal-title":"J Rheumatol."},{"issue":"3","key":"521_CR94","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.38984","volume":"67","author":"F De Benedetti","year":"2015","unstructured":"De Benedetti F, Brunner H, et al. Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. Arthritis Rheumatol. 2015 Mar;67(3):840\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"521_CR95","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1365-2265.2000.01122.x","volume":"53","author":"LL Elias","year":"2000","unstructured":"Elias LL, Huebner A, et al. Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf). 2000 Oct;53(4):423\u201330.","journal-title":"Clin Endocrinol (Oxf)."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00521-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:08:59Z","timestamp":1675040939000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00521-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00521-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}